Coverage
— → Added to coverage
Investment conviction●○○○○1 of 5
Research target—Stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed 7/14/26
Market cap$5.67BSnapshot value
Research history
See all BLLN changes ↗What changed
Molecular diagnostics with proprietary QCT technology for liquid biopsy; profitable in 2025, expanding from prenatal into oncology MRD/liquid biopsy with Northstar platform
No published catalysts yet.
No published invalidation criteria yet.
No social-sentiment snapshot available.
Snapshot · 7/14/26No positioning snapshot available.
Snapshot · 7/14/26